Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Average Recommendation of “Buy” by Brokerages

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) have received an average rating of “Buy” from the eight analysts that are covering the company, Marketbeat reports. Six analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $30.00.

A number of research firms have recently issued reports on ATXS. Cantor Fitzgerald restated an “overweight” rating and issued a $47.00 price target on shares of Astria Therapeutics in a research report on Wednesday, May 14th. Wedbush reissued an “outperform” rating and set a $28.00 target price (up previously from $27.00) on shares of Astria Therapeutics in a research note on Wednesday, March 12th. Finally, HC Wainwright restated a “buy” rating and issued a $16.00 price objective on shares of Astria Therapeutics in a report on Friday, June 13th.

Hedge Funds Weigh In On Astria Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Rhumbline Advisers grew its position in Astria Therapeutics by 2.3% during the 4th quarter. Rhumbline Advisers now owns 62,163 shares of the biotechnology company’s stock worth $556,000 after purchasing an additional 1,381 shares in the last quarter. Hsbc Holdings PLC grew its holdings in shares of Astria Therapeutics by 9.0% during the fourth quarter. Hsbc Holdings PLC now owns 19,263 shares of the biotechnology company’s stock valued at $170,000 after buying an additional 1,587 shares in the last quarter. Legal & General Group Plc raised its position in Astria Therapeutics by 7.6% during the fourth quarter. Legal & General Group Plc now owns 31,418 shares of the biotechnology company’s stock valued at $281,000 after buying an additional 2,222 shares during the period. Tower Research Capital LLC TRC lifted its stake in Astria Therapeutics by 109.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company’s stock worth $47,000 after acquiring an additional 2,766 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in Astria Therapeutics by 19.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 17,762 shares of the biotechnology company’s stock worth $159,000 after acquiring an additional 2,878 shares in the last quarter. Institutional investors and hedge funds own 98.98% of the company’s stock.

Astria Therapeutics Trading Up 3.3%

ATXS stock opened at $5.89 on Thursday. The firm has a 50 day simple moving average of $4.72 and a 200-day simple moving average of $6.50. The company has a market capitalization of $332.37 million, a P/E ratio of -3.15 and a beta of 0.39. Astria Therapeutics has a twelve month low of $3.56 and a twelve month high of $12.92.

Astria Therapeutics (NASDAQ:ATXS) last announced its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.10). On average, research analysts predict that Astria Therapeutics will post -1.65 EPS for the current year.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.